{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:10:45Z","timestamp":1776312645725,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100335","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T13:39:15Z","timestamp":1613050755000},"page":"100335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: \u201cAnd Yet It Moves!\u201d"],"prefix":"10.1016","volume":"27","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0001","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0003","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100335_bib0004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2021.100335_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ctarc.2021.100335_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9935","key":"10.1016\/j.ctarc.2021.100335_bib0007","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100335_bib0008","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100335_bib0009","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100335_bib0010","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.13517","article-title":"Risk estimation for biliary tract cancer: Development and validation of a prognostic score","volume":"37","author":"Schweitzer","year":"2017","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0012","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0013","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ags3.12266","article-title":"Essential updates to the surgical treatment of biliary tract cancer","volume":"3","author":"Matsukuma","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.ctarc.2021.100335_bib0014","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SLA.0000000000002385","article-title":"Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy","volume":"266","author":"Kasumova","year":"2017","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0016","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100335_bib0017","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0018","first-page":"1","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"18","author":"Rizzo","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0019","article-title":"Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives","author":"Sanoyan","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100335_bib0020","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.21873\/anticanres.12926","article-title":"Cholangiocarcinoma: CT-guided High-Dose Rate Brachytherapy (CT-HDRBT) for Limited (<4 cm) and Large (>4 cm) Tumors","volume":"38","author":"Jonczyk","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctarc.2021.100335_bib0021","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0022","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2021.100335_bib0023","first-page":"1","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","volume":"25","author":"Rizzo","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctarc.2021.100335_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","article-title":"Molecular characteristics of biliary tract cancer","volume":"107","author":"Sohal","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100335_bib0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0026","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New Treatment Options for Advanced Biliary Tract Cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100335_bib0028","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0029","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/cgp.20203","article-title":"Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives","volume":"17","author":"Rizzo","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.ctarc.2021.100335_bib0030","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/cancers12082190","article-title":"Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine","volume":"12","author":"Malenica","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2021.100335_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0032","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0034","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers12051237","article-title":"Biliary Tract Cancer: Current Medical Treatment Strategies","volume":"12","author":"Oneda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100335_bib0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ctarc.2021.100335_bib0036","article-title":"Emerging biomarkers in urothelial carcinoma: Challenges and opportunities","volume":"25","author":"Andreatos","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctarc.2021.100335_bib0037","article-title":"Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma","volume":"23","author":"Gulati","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctarc.2021.100335_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100335_bib0039","article-title":"Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis","volume":"27","author":"Rizzo","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctarc.2021.100335_bib0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820948047","article-title":"Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look","volume":"27","author":"Ricci","year":"2020","journal-title":"Cancer Control"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0042","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jjco\/hyy082","article-title":"New developments in systemic therapy for advanced biliary tract cancer","volume":"48","author":"Morizane","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729241","article-title":"Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma","volume":"24","author":"Chun","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctarc.2021.100335_bib0044","first-page":"1","article-title":"Recent advances of immunotherapy for biliary tract cancer","volume":"8","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0045","doi-asserted-by":"crossref","DOI":"10.21037\/jgo.2017.05.04","article-title":"Current biologics for treatment of biliary tract cancers","author":"Zhao","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0046","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1245\/s10434-016-5101-y","article-title":"Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma","volume":"23","author":"Gani","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0047","doi-asserted-by":"crossref","unstructured":"Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box? ESMO Open. 2020 Sep;5(5):e001042. doi: 10.1136\/esmoopen-2020-001042. PMID: 32994319; PMCID: PMC7526276.","DOI":"10.1136\/esmoopen-2020-001042"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082039","article-title":"Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0049","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2018.1512581","article-title":"Novel targeted treatment options for advanced cholangiocarcinoma","volume":"27","author":"Mahipal","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0051","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0052","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","article-title":"A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan","volume":"48","author":"Tsukiyama","year":"2017","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100335_bib0053","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0054","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.21873\/anticanres.14282","article-title":"Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow","volume":"40","author":"Rizzo","year":"2020","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100335_bib0055","first-page":"200","article-title":"Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctarc.2021.100335_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13703","article-title":"In Regard toA phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)","author":"Ricci","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0057","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/cco.2019.08.14","article-title":"Systemic therapy for gallbladder cancer","volume":"8","author":"Javle","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0058","first-page":"1","article-title":"Experimental HER2- targeted therapies for biliary tract cancer","volume":"6","author":"Rizzo","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0059","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","article-title":"Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer","volume":"50","author":"McNamara","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0060","first-page":"428","article-title":"A population based analysis of prognostic factors in advanced biliary tract cancer","volume":"5","author":"Peixoto","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0061","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000453084","article-title":"Systemic Therapy of Cholangiocarcinoma","volume":"32","author":"Plentz","year":"2016","journal-title":"Visc Med"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100335_bib0062","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100335_bib0063","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","article-title":"working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"123","author":"Marin","year":"2020","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0064","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/00365521.2019.1619827","article-title":"Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location","volume":"54","author":"Song","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0065","article-title":"Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer","volume":"9","author":"Rizzo","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100335_bib0066","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100335_bib0067","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0068","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100335_bib0069","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl_8","key":"10.1016\/j.ctarc.2021.100335_bib0070","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401- MITSUBA). In: ESMO Congress","volume":"29","author":"Sakai","year":"2018","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctarc.2021.100335_bib0071","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2017.35.4_suppl.427","article-title":"A UGT1A1 genotype- guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies. In: ASCO GI","volume":"35","author":"Sharma","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100335_bib0072","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12032-020-01386-6","article-title":"NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials","volume":"37","author":"Kapacee","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0073","article-title":"A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)","author":"McNamara","year":"2020","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.ctarc.2021.100335_bib0074","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2020-0247","article-title":"NUC-1031\/cisplatin versus gemcitabine\/cisplatin in untreated locally advanced\/metastatic biliary tract cancer (NuTide:121)","volume":"16","author":"McNamara","year":"2020","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cells9030688","article-title":"New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100335_bib0076","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: Looking outside the box","volume":"72","author":"Faivre","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100335_bib0077","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/fon-2015-0012","article-title":"Immunotherapy for small-cell lung cancer: emerging evidence","volume":"12","author":"Reck","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0078","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","author":"Rizzo","year":"2021","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100335_bib0079","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/imt-2016-0142","article-title":"Immunotherapy for pancreatic cancer: present and future","volume":"9","author":"Aroldi","year":"2017","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma","volume":"4","author":"H\u00f8gdall","year":"2018","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0081","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100335_bib0082","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0083","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0084","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0086","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctarc.2021.100335_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101998","article-title":"Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation","volume":"86","author":"Athauda","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"10.1016\/j.ctarc.2021.100335_bib0088","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100335_bib0089","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3748\/wjg.v22.i4.1335","article-title":"Molecular genetics and targeted therapeutics in biliary tract carcinoma","volume":"22","author":"Marks","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0090","doi-asserted-by":"crossref","unstructured":"Jusakul A, Cutcutache I, Yong CH, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 2017 Oct;7(10):1116-1135. doi: 10.1158\/2159-8290.CD-17-0368. Epub 2017 Jun 30. PMID: 28667006; PMCID: PMC5628134.","DOI":"10.1158\/2159-8290.CD-17-0368"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0091","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"4 Pt B","key":"10.1016\/j.ctarc.2021.100335_bib0092","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.08.027","article-title":"Targeting cholangiocarcinoma","volume":"1864","author":"Mertens","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0093","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100335_bib0094","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100335_bib0095","first-page":"2","article-title":"Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers","volume":"8","author":"Papadopoulou","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100335_bib0096","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarci- noma","volume":"24","author":"Sohal","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100335_bib0097","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100335_bib0098","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxalipla- tin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100335_bib0099","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.ctarc.2021.100335_bib0100","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and Translational Research Challenges in Biliary Tract Cancers","volume":"27","author":"Lamarca","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ctarc.2021.100335_bib0101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.028","article-title":"PICCA study: panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker- driven clinical phase II AIO study","volume":"92","author":"Vogel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctarc.2021.100335_bib0102","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctarc.2021.100335_bib0103","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combi- nation with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0104","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100335_bib0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ctarc.2021.100335_bib0106","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3748\/wjg.v23.i14.2470","article-title":"Biliary tract cancer stem cells - translational options and challenges","volume":"23","author":"Mayr","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctarc.2021.100335_bib0107","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100335_bib0108","doi-asserted-by":"crossref","first-page":"e1818","DOI":"10.1634\/theoncologist.2020-0385","article-title":"HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer","volume":"25","author":"Rizzo","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0109","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100335_bib0110","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/cancers12092599","article-title":"Recent Progress in the Systemic Treatment of Advanced\/Metastatic Cholangiocarcinoma","volume":"12","author":"Fostea","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100335_bib0111","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:43Z","timestamp":1762842163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":111,"alternative-id":["S2468294221000344"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100335","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: \u201cAnd Yet It Moves!\u201d","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100335"}}